Optimal use of G-CSF administration after hematopoietic SCT

Clinical factors affecting engraftment and transfusion needs in SCT: a single-center retrospective analysis

“…G-CSFs have also been utilized after allografting and with cord blood transplant, but more controversy surrounds their use in those settings. 5 Conditioning regimens for hematopoietic SCT vary in degree or the intensity of myeloablative and immune suppressive potential. Some regimens incorporate total body radiation, whereas others use combination chemotherapy without total body radiation.…”

Retrospective comparison of the effects of filgrastim and pegfilgrastim on the pace of engraftment in auto-SCT patients

“…[1][2][3] In addition, it has been shown that the duration of grade 4 neutropenia in the post transplant setting has a major effect on overall morbidity and mortality. [4][5] Filgrastim is a recombinant human G-CSF that stimulates the production of neutrophil precursors and thereby reduces the duration of neutropenia and associated complications. 6 Various studies have shown that the administration of filgrastim post transplant significantly reduces the time to neutrophil recovery.…”

CCR7 impairs hematopoiesis after hematopoietic stem cell transplantation increasing susceptibility to invasive aspergillosis

“…Thus, one goal of HSCT clinical research has been to enhance the engraftment and immune reconstitution of hematopoietic cells to restore a functional immune system within the patient. 38,39 Examination of the BM and spleen of CCR7 Ϫ/Ϫ mice revealed a significant increase in the numbers and percentages of HSCs and GMPs in these mice, compared with WT mice. In addition, when equivalent numbers of WT and CCR7 Ϫ/Ϫ HSCs and MPCs were used to reconstitute lethally irradiated WT mice, the number of myeloid cells originating from CCR7-deficient HSCs was significantly greater than the number of myeloid cells derived from WT HSCs.…”